• Legend Biotech seeks shareholder approval to amend its 2020 restricted shares plan, adding 19,100,000 ordinary shares to the issuance pool.
• Total reserve would rise to 45,100,000 ordinary shares from 26,000,000, effective Sept. 24, 2026 if adopted.
• The added reserve equals 4.9% of ordinary shares outstanding as of Aug. 17, 2026.
• Shares remaining for grant under the plan stood at 5,257,658 as of June 30, 2026.
• Separate equity overhang included 15,635,609 ordinary shares under outstanding awards; options carried a weighted-average exercise price of USD 10.32.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Legend Biotech Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005623), on August 18, 2026, and is solely responsible for the information contained therein.